Trikafta/Kaftrio and Pseudomonas Aeruginosa

Cystic Fibrosis Clinical Trial

— Kaf-Pseudo  

Official title:

Linking Elexacaftor/Tezacaftor/Ivacaftor to Infections in Cystic Fibrosis Lung Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05675592
• Other study ID #: 173/INT/2021
• Secondary ID: FFC#16/2021
• Status: Recruiting
• Start date: February 22, 2022
• Est. completion date: May 16, 2025

Study information

• Verified date: January 2023
• Source: Ospedale San Raffaele
• Contact: Cristina Cigana, PhD
• Phone: +390226434138
• Email: cigana.cristina[@]hsr.it
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this observational study o is to define whether, how and to what extent treatment with Trikafta/Kaftrio directly affects Pseudomonas aeruginosa in individuals with cystic fibrosis. The main questions it aims to answer are: - whether Trikafta/Kaftrio affects the bacterial phenotypes and susceptibility to antibiotics; - whether Trikafta/Kaftrio impacts the bacterial virulence. Participants will be asked the permission to store and analyze P. aeruginosa isolates collected from respiratory samples for usual care plans before the initiation of treatment with Trikafta/Kaftrio and after 12 and 18 months of treatment. The results of bacterial analysis will be matched with clinical data at the specific time-points. We expect to define effects of Trikafta/Kaftrio on P. aeruginosa and identify bacterial phenotypes as possible risk factors for its efficacy.

Description:

We will recruit 20 individuals affected by cystic fibrosis (≥12 years of age), chronically infected with P. aeruginosa (defined as having at least 50% or more sputum cultures positive for P. aeruginosa in the previous year), homozygous for the F508del mutation (F508del/F508del) or heterozygous for the F508del mutation and with a minimal function mutation in the other allele (F508del/minimal function), candidates for treatment with Trikafta/Kaftrio according to clinical practice. P. aeruginosa strains will be collected from the sputum before the start of therapy (T0) and after 12 (T12m) and 18 (T18m) months of treatment with Trikafta/Kaftrio. Currently, some patients have already started treatment with Trikafta/Kaftrio. The strains at T0 and for some of them also at T12m and T18m have already been recovered from these patients for other studies. Of these strains it is not yet known whether they are clonal at different times (T0, T12m and T18m). Of these patients, we will include in the expected 20 (20 total between prospective and retrospective) only patients for whom strains clonal between T0, T12m and T18m will be identified, asking for their authorization to use the strains and their data through informed consent. If the number of retrospective patients is sufficient to reach the expected number (20 total patients), no other patients will be recruited prospectively. Patients who will be prescribed Trikafta/Kaftrio therapy according to clinical practice will be recruited at routine visits. The decision to prescribe treatment with Trikafta/Kaftrio, according to current clinical practice, is completely independent of the decision to include the patient in this study. The diagnostic and evaluation procedures and follow-up visits foreseen by the study will coincide with those programmed for each patient according to the standard operating procedures in force at the participating centres. For retrospective patients, informed consent will be collected during the routine check-up and, once the eligibility criteria have been verified, the data relating to the visit performed before the start of therapy (T0) and, if already available, the data relating to the visit performed at 12 and 18 months from the beginning of the therapy (T12m and T18m), will be collected. P. aeruginosa recovered from the respiratory samples during the three visits will be analysed. In the event that data are not available, data and samples will be collected at the respective routine follow-ups (at 12 and/or 18 months). For prospective patients, the enrollment visit will be performed during the routine visit performed before the start of therapy (T0) which will be followed by visits scheduled for clinical practice at 12 and 18 months from the start of therapy (T12m and T18m). At T0, T12m and T18m the sputum samples, collected from the patient's airways, will be treated according to standard procedures for the evaluation of the bacterial species present. P. aeruginosa strains will be subjected to minimal inhibitory concentration tests to assay their susceptibility to a panel of standard antibiotics, and analyzed by Multi-locus Sequence Typing to detect their clonality. The strains of each patient that will be clonal between T0, T12m and T18m, immediately stored at -80°C, will then be shipped to Ospedale San Raffaele , where they will be analyzed for the purposes of the project using methods validated in the literature. We will analyze i) the phenotypes (in particular motility by pilus, motility by flagellum, secretion of proteases and pyocyanin, and mucoidity) of P. aeruginosa strains using microbiological methods validated in the literature, ii) the expression profiles of the strains by RNA sequencing, iii) the presence of gene variants by whole genome sequencing of the strains, iv) and their virulence by measuring their impact on the expression of the cystic fibrosis transmembrane conductance regulator protein in cystic fibrosis bronchial epithelial cell lines. The final aim will be to i) evaluate the differences in the phenotypes of the P. aeruginosa strains isolated at T0 and those isolated at T12m and T18m post treatment with Kaftrio; ii) to evaluate differences in the susceptibility to antibiotics of the P. aeruginosa strains isolated at T0 and those isolated at T12m and T18m; iii) evaluate differences in the expression profiles of the P. aeruginosa strains isolated at T0 and those isolated at T12m and T18m and correlate them to the difference in respiratory function measured as FEV1 (%); iv) evaluate the presence of gene variants between the strains isolated at T0 and those isolated at T12m and T18m and correlate them to the difference in respiratory function measured as FEV1 (%); v) to determine whether changes in bacterial phenotypes induced by Kaftrio treatment may be associated with lower anti-CFTR activity of P. aeruginosa.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: May 16, 2025
• Est. primary completion date: November 16, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• Definite diagnosis of CF and regular follow up, in accordance with the standard operating procedures in force at the Centres
• Homozygous for the F508del mutation (F508del/F508del) in the CFTR gene or heterozygous for the F508del mutation and with a minimal function mutation in the other allele (F508del/minimum function mutation)
• Chronically infected with P. aeruginosa (defined as having at least 50% or more sputum cultures positive for P. aeruginosa in the previous year)
• Candidates starting treatment with Kaftrio or being treated with Kaftrio (retrospective phase)
• Both sexes aged >12 years
• Obtaining informed consent from patients and/or from patients' parents (according to the modalities foreseen by the protocol)

Exclusion Criteria:

• Patients unable to understand the instructions and information provided and to be able to adequately accept the modalities of the study.
• Patients unable to expectorate.
• Patients with negative sputum for P. aeruginosa at T0, which in the case of prospective patients corresponds to the time of enrollment.

Related Conditions & MeSH terms

• Cystic Fibrosis
• Fibrosis

Locations

Country	Name	City	State
Italy	UOC Pediatria Fibrosi Cistica, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	Milan
Italy	UOC Fibrosi Cistica, IRCCS Ospedale Pediatrico Bambino Gesù	Rome

Sponsors (3)

Lead Sponsor	Collaborator
Ospedale San Raffaele	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Ospedale Pediatrico Bambin Gesù

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	bacterial phenotypes	motility by pilus, motility by flagellum, secretion of proteases, secretion of pyocyanin of P. aeruginosa strains isolated at T0 and clonal ones isolated at T12m and T18m post treatment with Trikafta/Kaftrio	0-18 months
Primary	respiratory function	respiratory function, evaluated as FEV1 (%), measured at time at T0, T12m and T18m post Trikafta/Kaftrio treatment	0-18 months
Secondary	susceptibility to antibiotics	susceptibility of P. aeruginosa strains isolated at T0 and those isolated at T12m and T18m to standard antibiotics evaluated by minimal inhibitory concentration assays	0-18 months
Secondary	mucoidy	mucoidy of the P. aeruginosa strains isolated at T0 and those isolated at T12m and T18m determined by visual assessment of the growth in the plate	0-18 months
Secondary	expression profile	expression profiles of the P. aeruginosa strains isolated at T0 and those isolated at T12m and T18m evaluated by RNA sequencing	0-18 months
Secondary	genetic variants	presence of gene variants, identified by whole genome sequencing, between the strains isolated at T0 and those isolated at T12m and T18m	0-18 months
Secondary	impact on CFTR	Membrane expression of CFTR protein, measured by western blot, in FC and non-FC immortalized bronchial epithelial cell lines stimulated with growth media of P. aeruginosa strains isolated at T0 and those isolated at T12m and T18m	0-18 months

External Links

•   project behind this study